Helicon Degraders Show a New Path in Prostate Cancer Therapy

In one of the most compelling advances for prostate cancer biology in recent years, a novel peptide-based degrader has achieved potent, selective elimination of the transcription factor ERG, an oncogenic driver long considered unreachable by medicinal chemistry. The discovery has upended conventional views on druggability in TMPRSS2–ERG fusion–positive prostate cancers, which comprise nearly half of all cases and are frequently linked to aggressive disease. By inducing over 90% depletion of ERG protein in multiple animal models, this pharmacological breakthrough provides the first functional validation that ERG is not only a hallmark of these tumors but also their therapeutic vulnerability.

The Helicon class of agents that enabled this success relies on stabilized helical peptide scaffolds capable of binding directly to protein surfaces historically resistant to small molecules. In this case, the Helicon degrader binds to ERG and simultaneously recruits an E3 ligase, marking the transcription factor for ubiquitin–proteasome–mediated clearance. This engineered mechanism accomplishes what decades of inhibitor-based chemistry could not, direct elimination of a lineage-specific oncogenic driver responsible for disrupting normal gene regulation in prostate cells.

In mouse models of TMPRSS2–ERG fusion prostate cancer, both xenograft and patient-derived, a single administration of the ERG Helicon degrader led to persistent suppression of ERG activity for at least a week. Downstream, ERG-regulated transcripts such as *ARHGDIB* were repressed, and MYC target gene programs were sharply attenuated, molecular signals of oncogenic quiescence. The consequence was strong inhibition of tumor growth, validating ERG as a druggable dependency for the first time.

The implications for therapy development are significant. ERG fusions have not only been correlated with poor patient outcomes but also with resistance to androgen receptor–directed drugs and PARP inhibitors. By integrating ERG degradation with complementary approaches such as AR degraders, this dual-axis targeting could overcome adaptive resistance and deliver deeper tumor control in advanced or castration-resistant prostate cancer. Notably, early-stage molecules from the same Helicon platform are being optimized to degrade activated AR species that evade blockade by enzalutamide or darolutamide, suggesting a synergistic therapeutic horizon.

Source.